Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01259921 · ClinicalTrials.gov registry record · NA

EEG Biofeedback in the Treatment of Chronic Treatment-Resistant PTSD

A NA study of Post Traumatic Stress Disorder, sponsored by Justice Resource Institute.

Completed
Registry status
NA
Development phase
52
Enrollment target
1
Study location

NCT01259921: Completed NA study of Post Traumatic Stress Disorder, sponsored by Justice Resource Institute.

NCT01259921 is a NA study of Post Traumatic Stress Disorder that has completed, run by Justice Resource Institute. The registered enrollment target is 52 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01259921, a NA study of Post Traumatic Stress Disorder, has completed, sponsored by Justice Resource Institute.

COMPLETED
Registry status
NA
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether neurofeedback (NF) training can significantly reduce the symptoms of Posttraumatic Stress Disorder (PTSD) in individuals with significant affect dysregulation and chronic, treatment-resistant PTSD. The primary aims of this study include: 1. To examine whether NF has the potential to significantly reduce symptoms of PTSD. 2. To examine whether NF training can specifically target the area of affect regulation. 3. To examine the mechanism of NF through elucidating the relationship between affect regulation and PTSD symptom change.

Primary Outcome

The CAPS is considered the gold standard for the assessment of PTSD (National Center for PTSD Research). It is a clinician administered 30-item interview that corresponds to DSM-IV criteria for PTSD. Each item of the CAPS has two parts, frequency and intensity, which are both scored on a 5-point scale from 0 to 4. A general cut-off rule of frequency greater than or equal to 1 and intensity greater than or equal to 2 for a symptom to count towards diagnosis will be employed in assigning PTSD diag

Conditions Studied

Post Traumatic Stress Disorder

Interventions

  • BEHAVIORAL neurofeedback

Study Locations (1)

Massachusetts

  • the Trauma Center at JRI - Brookline

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2009-12
Est. Completion 2012-12
Phase NA
Justice Resource Institute

2 total trials

What the finished NCT01259921 record still lists

NCT01259921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 1 intervention - of which neurofeedback is the first listed.

NCT01259921 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01259921 about?

NCT01259921 is a clinical study titled "EEG Biofeedback in the Treatment of Chronic Treatment-Resistant PTSD". The purpose of this study is to determine whether neurofeedback (NF) training can significantly reduce the symptoms of Posttraumatic Stress Disorder (PTSD) in individuals with significant affect dysregulation and chronic, treatment-resistant PTSD. The primary aims of this study include: 1. To exami...

What is the current status of trial NCT01259921?

This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2009-12. Estimated completion is 2012-12.

What conditions does trial NCT01259921 study?

This clinical trial studies the following conditions: Post Traumatic Stress Disorder.

What interventions are being tested in trial NCT01259921?

The interventions under investigation include: neurofeedback (BEHAVIORAL).

Who is sponsoring clinical trial NCT01259921?

This trial is sponsored by Justice Resource Institute, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01259921 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Post Traumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01259921's enrollment target sits among peer trials

52 175th of 262 higher than 88 of 262 other Post Traumatic Stress Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01259921, the US trial registry maintained by the National Library of Medicine. NCT01259921 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.